The Roche Group’s multiple sclerosis drug Ocrevus (ocrelizumab) generated sales of CHF 1.4 billion ($1.44 billion) in the first quarter of 2022 making it the company’s top-selling drug – ahead of the cancer treatments Perjeta and Tecentriq. Group sales for the quarter were CHF 16.4 billion, up by 10% in Swiss francs from a year earlier and by 11% in constant exchange rates. Roche does not report operating or net income figures on a quarterly basis. But the company did say it expects to increase its dividend for the year.
